Abstract
(2011). Eribulin mesylate for the treatment of late-stage breast cancer. Expert Opinion on Pharmacotherapy: Vol. 12, No. 18, pp. 2883-2890. doi: 10.1517/14656566.2011.637490

This publication has 21 references indexed in Scilit: